Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer. (Q46983422)

PubMed publication ID

27053499

27 December 2017

http://europepmc.org/abstract/MED/27053499

title

Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

13 May 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

13 May 2020

author name string

Dipenkumar Modi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

13 May 2020

Clara Hwang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

13 May 2020

Hirva Mamdani

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

13 May 2020

Seongho Kim

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

13 May 2020

Hesham Gayar

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

13 May 2020

Richard Joyrich

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

13 May 2020

Elisabeth I Heath

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

13 May 2020

language of work or name

English

0 references

publication date

10 March 2016

1 reference

PubMed publication ID

27053499

27 December 2017

http://europepmc.org/abstract/MED/27053499

published in

Clinical Genitourinary Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

13 May 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

13 May 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

13 May 2020

page(s)

373-380.e2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

Alpha emitter radium-223 and survival in metastatic prostate cancer

13 May 2020

cites work

1 reference

12 December 2020

Mechanisms of bone metastasis

1 reference

12 December 2020

Cancer statistics, 2015

1 reference

12 December 2020

Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223

1 reference

12 December 2020

A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.

1 reference

12 December 2020

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

1 reference

12 December 2020

One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer

1 reference

12 December 2020

A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

12 December 2020

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, [...]

1 reference

12 December 2020

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases

1 reference

12 December 2020

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report

1 reference

12 December 2020

Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.

1 reference

12 December 2020

Implications of bone metastases and the benefits of bone-targeted therapy

1 reference

12 December 2020

10.1016/J.CLGC.2016.03.002

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6849387&resulttype=core&format=json

13 May 2020

PubMed publication ID

27053499

1 reference